Skip to Content

Cannabis Science Receives New Photos and Information on Patient Three's Previous Examinations and the Current Progress on his Severe Squamous Cell Carcinoma

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--May 16, 2012 - Cannabis Science, Inc. (OTCBB:CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to provide the latest photos and information on patient three's progress.

Cannabis Science continues to work closely with its third patient, who is self-treating his otherwise resistant Squamous Cell Carcinoma. The patient has seen dramatic improvements. He has been applying a topical cannabis extract to his cancer, and has seen a large reduction in the tumor masses. Dr. Melamede spoke with the patient this morning, who stated that 80% of the rim that remained from the large tumor on the left side of his head was now gone. The newly posted photo was from over a week ago.

After his last visit to his oncologist (prior to the newly posted photo), the physician explained that he is concerned there may be more tumors on his head that have not yet manifested. The oncologist then instructed the patient to apply the cannabis extracts to his entire scalp. As a result of more extensive topical application of the medicine, new areas have reemerged and are also dying. For example, a new tumor emerged below his hairline. He treated that tumor in the same manner as he has treated the others. He reported that the new tumor had fallen off and left a small hole, similar to what had occurred on his arm (we have not shown these tumors). The rise and fall of the new tumor will be photo-documented when we receive new photos.

Despite the severe pain resulting from additional exposed areas as more tumor mass dies, he is happy to have chosen this route of treatment as opposed to surgery that would have remove most of his scalp and a good portion of the top of his skull. In order to help with the pain and allow for better sleep, the patient is also now taking the extract internally.

The patient stated, "As for my head... the oncologist was amazed by the progress... as the one tumor on my right side is now almost down to conforming with the natural shape of my head and he thinks the others are being killed off too but predicted it might be a couple more months before he could declare it works... Cautious optimism. Also the doctor said that he is hopeful that this works, as there is no known chemo that cures this type of cancer."

You can view these new photos on the Cannabis Science website and click the button “View Images of 3rd Self-Medicated Patient & His Apparent Success.” You can read more news on this 3rd patient as well on the Cannabis Science website at and click on the breaking news button where you will find all the cancer related and updated patient news.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.


Contact: Cannabis Science Inc.
Dr. Robert J. Melamede
President & CEO
Robert Kane
VP Investor Relations



Posted: May 2012